A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

被引：6

作者：

Assouline, Sarit ^{[1
]}

Michaelis, Laura C. ^{[2
]}

Othus, Megan ^{[3
]}

Hay, Annette E. ^{[4
]}

Walter, Roland B. ^{[5
]}

Jacoby, Meagan A. ^{[6
]}

Schroeder, Mark A. ^{[6
]}

Uy, Geoffrey L. ^{[6
]}

Law, Lisa Y. ^{[7
]}

Cheema, Faisal ^{[8
]}

Sweet, Kendra L. ^{[9
]}

Asch, Adam S. ^{[10
]}

Liu, Jijun ^{[11
]}

Moseley, Anna B. ^{[2
]}

Maher, Tracy ^{[12
]}

Kingsbury, Laura L. ^{[12
]}

Fang, Min ^{[5
]}

Radich, Jerald ^{[5
]}

Little, Richard F. ^{[13
]}

Erba, Harry P. ^{[14
]}

机构：

[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[2] Med Coll Wisconsin, Milwaukee, WI USA

[3] SWOG Stat & Data Management Ctr, Seattle, WA USA

[4] Queens Univ, Kingston, ON, Canada

[5] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Washington Univ, Sch Med, St Louis, MO USA

[7] Kaiser Permanente NCAL, Roseville, CA USA

[8] Kaiser Permanente, Santa Clara, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Oklahoma HSC, Oklahoma City, OK USA

[11] Illinois Canc Care Heartland NCORP, Peoria, IL USA

[12] SWOG Data Operat Ctr, Canc Res & Biostat, Seattle, WA USA

[13] Natl Canc Inst, Canc Therapy & Evaluat Program CTEP, Bethesda, MD USA

[14] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 02期

基金：

美国国家卫生研究院;

关键词：

CONVENTIONAL-CARE-REGIMENS; THERAPY;

D O I：

10.1080/10428194.2022.2148212

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：473 / 477

页数：5

共 50 条

[21] Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib plus azacitidine (AZA).
Wang, Eunice S.
Bell, Timothy
Zeidan, Amer Methqal
Bhattacharyya, Helen
Kudla, Art
Chan, Geoffrey
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
Zeidan, Amer Methqal
Schuster, Michael
Joris, Magalie
Krauter, Jurgen
Maertens, Johan
Gyan, Emmanuel
Kovacsovics, Tibor
Verma, Amit
Vyas, Paresh
Wang, Eunice S.
Ma, Wendy
Zeremski, Mirjana
Kudla, Art
Chan, Geoffrey
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Naval, Daver
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Pemmaraju, Naveen
Kadia, Tapan M.
DiNardo, Courtney D.
Jain, Nitin
Borthakur, Gautam
Jabbour, Elias
Konopleva, Marina
Cortes, Jorge E.
Craig, Adam
Ravandi, Farhad
BLOOD, 2014, 124 (21)
[24] A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia
Iida, Hiroatsu
Imada, Kazunori
Ueda, Yasunori
Kubo, Kohmei
Yokota, Akira
Ito, Yoshikazu
Kiguchi, Toru
Hata, Tomoko
Nawa, Yuichiro
Ikezoe, Takayuki
Uchida, Toshiki
Morita, Yasuyoshi
Kawashima, Ichiro
Chiba, Masahiro
Morimoto, Kensaku
Hirooka, Shihomi
Miyazaki, Yasushi
Ohno, Ryuzo
Naoe, Tomoki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (05) : 694 - 703
[25] A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia
Hiroatsu Iida
Kazunori Imada
Yasunori Ueda
Kohmei Kubo
Akira Yokota
Yoshikazu Ito
Toru Kiguchi
Tomoko Hata
Yuichiro Nawa
Takayuki Ikezoe
Toshiki Uchida
Yasuyoshi Morita
Ichiro Kawashima
Masahiro Chiba
Kensaku Morimoto
Shihomi Hirooka
Yasushi Miyazaki
Ryuzo Ohno
Tomoki Naoe
International Journal of Hematology, 2022, 115 : 694 - 703
[26] Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Zhou, Xiaofei
Mould, Diane R.
Zhao, Dan
Sekeres, Mikkael A.
Ades, Lionel
Swords, Ronan T.
Handa, Hiroshi
Fram, Robert J.
Faller, Douglas V.
Tsukurov, Olga
Gupta, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Daver, Naval
Konopleva, Marina
Maiti, Abhishek
Kadia, Tapan M.
DiNardo, Courtney D.
Loghavi, Sanam
Pemmaraju, Naveen
Jabbour, Elias J.
Montalban-Bravo, Guillermo
Tang, Guilin
Sasaki, Koji
Borthakur, Gautam
Yilmaz, Musa
Alvarez, Joie
Golez, Michelle
Pierce, Sherry A.
Nogueras Gonzalez, Graciela M.
Ning, Jing
Abbas, Hussein A.
Ravandi, Farhad
Garcia-Manero, Guillermo
Kantarjian, Hagop
BLOOD, 2021, 138
[28] Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)
Kadia, Tapan M.
Benton, Christopher
Erba, Harry P.
Gandhi, Mitul
Levy, Moshe Y.
Percival, Mary-Elizabeth M.
Ulrickson, Matthew
Yimer, Habte
Yu, Min
Chen, Zi
Wang, Jing
Li, Mingyu
Ahmad, Mohammad
Yang, Dajun
Zhai, Yifan
BLOOD, 2022, 140 : 11659 - 11660
[29] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Borate, U.
Smith, B. D.
Gore, S.
Zeidan, A.
Savona, M.
Savoie, M. L.
Zhu, N.
Breems, D.
Zhang, X.
Shaik, M. N.
Rampersad, A.
Chan, G.
Woolfson, A.
Sekeres, M.
HAEMATOLOGICA, 2016, 101 : 73 - 74
[30] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Daver, Naval Guastad
Kantarjian, Hagop M.
Pierce, Sherry
Brandt, Mark
Dinardo, Courtney Denton
Pemmaraju, Naveen
Vaughan, Kenneth
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan M.
Cortes, Jorge E.
Craig, Adam
Ravandi, Farhad
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →